Management of Recurrent Hepatitis C Infection after Liver Transplantation

Limaye, Alpna R.; Firpi, Roberto J.

doi:10.1016/j.cld.2011.08.003

Cited by 2 publications

(2 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the United States and Europe, end-stage liver disease associated with HCV infection has become the leading indication for liver transplantation (Limaye and Firpi, 2011). HCV recurrence is one of the risk factors associated with a worse outcome after transplantation.…”

Section: Introductionmentioning

confidence: 99%

Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells

Zhang

et al. 2012

Virus Research

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is the most common indication for liver transplantation and the major cause of graft failure. A widely used immunosuppressant, cyclosporine A (CsA), for people who receive organ transplantation, has been recognized to have the ability to inhibit HCV replication both in vivo and in vitro. In this study, we investigated the effects of several other immunosuppressants, including mycophenolate mofetil (MMF), rapamycin and FK506, on HCV replication in human hepatic cells. MMF treatment of hepatic cells before or during HCV infection significantly suppressed full cycle viral replication, as evidenced by decreased expression of HCV RNA, protein and production of infectious virus. In contrast, rapamycin and FK506 had little effect on HCV replication. Investigation of the mechanism(s) disclosed that the inhibition of HCV replication by MMF was mainly due to its depletion of guanosine, a purine nucleoside crucial for synthesis of guanosine triphosphate, which is required for HCV RNA replication. The supplement of exogenous guanosine could reverse most of anti-HCV effect of mycophenolate mofetil. These data indicate that MMF, through the depletion of guanosine, inhibits full cycle HCV JFH-1 replication in human hepatic cells. It is of interest to further determine whether MMF is indeed beneficial for HCV-infected transplant recipients in future clinical studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells

Zhang

et al. 2012

Virus Research

View full text Add to dashboard Cite

show abstract

“…Recurrent hepatitis C (HCV) infection is a universal phenomenon after liver transplantation, and exhibits an accelerated progression to advanced liver disease [27]. Particularly in the early months after transplant, the differential diagnosis of abnormal liver enzymes in HCV patients includes both ACR and recurrent HCV.…”

Section: Recurrent Hepatitis Cmentioning

confidence: 99%